Bentley, Cardinal Health to Scale-Up Clinical Supplies for Intranasal Insulin - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Bentley, Cardinal Health to Scale-Up Clinical Supplies for Intranasal Insulin

ePT--the Electronic Newsletter of Pharmaceutical Technology

Untitled Document

Exeter, NH (Sept. 19)—Specialty pharmaceutical company Bentley Pharmaceuticals ( has entered into an agreement with Cardinal Health (Dublin, OH, for the scale-up of clinical supplies for Bentley’s intranasal insulin product candidate. Under current good manufacturing practices, Cardinal’s North Raleigh (NC) facility will manufacture clinical supplies for Bentley’s “CPE-125” drug delivery technology. The companies previously collaborated at Cardinal’s Research Triangle Park (NC) facility, where the product was characterized.

The platform is designed to deliver insulin through a patient’s nasal mucosa via a small nasal spray. Bentley expects to continue its intranasal insulin program through global Phase II trials this year, according to a statement by company president John A. Sedor.

On Sept. 6, 2006, Cardinal announced it had won approval from the US Food and Drug Administration to begin production at its sterile facility in North Raleigh. Ovation Pharmaceutical’s ( “Panhematin” (hemin for injection) was the first commercial drug to be manufactured at the new facility, which was built in 1997 and acquired when Cardinal bought Magellan Labs in 2001.



blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here